Literature DB >> 16566534

Long-term follow-up of patients treated for toxic epidermal necrolysis.

Agnes Oplatek1, Kimberly Brown, Soman Sen, Marcia Halerz, Kathy Supple, Richard L Gamelli.   

Abstract

Patient outcomes concerning toxic epidermal necrolysis (TEN) have improved over the years as a better understanding of the pathophysiology of the illness has been gained and enhancements have been made in the care of the acutely ill. With increase in survival, long-term complications these patients experience are beginning to be recognized. In this study, we analyzed the outcomes of a cohort of TEN survivors treated at our burn unit and sought to determine the impact of clinical variables from the initial hospitalization on mortality after discharge. We performed a retrospective review of data from patients with TEN treated at our burn unit from March 1993 to September 2002. Follow-up data on new health problems were collected on patients who were alive at discharge via questionnaire. Survival was estimated using the Kaplan-Meier method with Cox regression model. During the study period, of the 64 patients treated for TEN, 46 survived. After discharge, 15 patients died, whereas the remaining 31 patients continued to suffer from ocular (54%), skin (81%), and renal (23%) problems. Median survival for the whole cohort has not been reached, with an estimated 5-year survival of 65%. No patient in either group had a TEN recurrence. Seventy-nine percent of the patients with ocular involvement in the acute phase of TEN had long-term ocular complications, and 73% of patients with mucosal involvement had persistent mucosal lesions. Five individual factors were found to be predictors of postdischarge mortality on univariate analysis: age at diagnosis of TEN>or=60 years, SCORTEN 3 to 6, % maximal TBSA slough>or=50%, days from onset of symptoms to admission to a burn unit>or=5 days, and presence of multiple comorbidities at diagnosis of TEN. In multivariate analysis, only SCORTEN of 3 to 6 (P=.003) and days to admission>or=5 (P=.027) maintained significance as predictors of mortality and may be used to heighten surveillance during postdischarge care of patients with TEN.

Entities:  

Mesh:

Year:  2006        PMID: 16566534     DOI: 10.1097/01.bcr.0000194268.01514.f8

Source DB:  PubMed          Journal:  J Burn Care Res        ISSN: 1559-047X            Impact factor:   1.845


  17 in total

1.  Stevens-Johnson syndrome/toxic epidermal necrolysis: are drug dictionaries correctly informing physicians regarding the risk?

Authors:  Cynthia Haddad; Alexis Sidoroff; Sylvia H Kardaun; Maja Mockenhaupt; Daniel Creamer; Ariane Dunant; Jean-Claude Roujeau
Journal:  Drug Saf       Date:  2013-08       Impact factor: 5.606

2.  Long-Term Effect of a Treatment Protocol for Acute Ocular Involvement in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.

Authors:  Swapna S Shanbhag; Ramy Rashad; James Chodosh; Hajirah N Saeed
Journal:  Am J Ophthalmol       Date:  2019-07-19       Impact factor: 5.258

3.  A cross-sectional comparative study on chronic ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese eyes: a 15-year case series.

Authors:  Loraine L W Chow; Alex L K Ng; Sharon S W Chow; Bonnie N K Choy; Kendrick C Shih; Ian Y H Wong; Johnny C Y Chan; Jimmy S M Lai
Journal:  Int Ophthalmol       Date:  2017-05-25       Impact factor: 2.031

4.  New insights in toxic epidermal necrolysis (Lyell's syndrome): clinical considerations, pathobiology and targeted treatments revisited.

Authors:  Philippe Paquet; Gérald E Piérard
Journal:  Drug Saf       Date:  2010-03-01       Impact factor: 5.606

5.  Sutureless amniotic membrane transplantation with cyanoacrylate glue for acute Stevens-Johnson syndrome/toxic epidermal necrolysis.

Authors:  Swapna S Shanbhag; James Chodosh; Hajirah N Saeed
Journal:  Ocul Surf       Date:  2019-03-11       Impact factor: 5.033

Review 6.  SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation.

Authors:  Katie D White; Riichiro Abe; Michael Ardern-Jones; Thomas Beachkofsky; Charles Bouchard; Bruce Carleton; James Chodosh; Ricardo Cibotti; Robert Davis; Joshua C Denny; Roni P Dodiuk-Gad; Elizabeth N Ergen; Jennifer L Goldman; James H Holmes; Shuen-Iu Hung; Mario E Lacouture; Rannakoe J Lehloenya; Simon Mallal; Teri A Manolio; Robert G Micheletti; Caroline M Mitchell; Maja Mockenhaupt; David A Ostrov; Rebecca Pavlos; Munir Pirmohamed; Elena Pope; Alec Redwood; Misha Rosenbach; Michael D Rosenblum; Jean-Claude Roujeau; Arturo P Saavedra; Hajirah N Saeed; Jeffery P Struewing; Hirohiko Sueki; Chonlaphat Sukasem; Cynthia Sung; Jason A Trubiano; Jessica Weintraub; Lisa M Wheatley; Kristina B Williams; Brandon Worley; Wen-Hung Chung; Neil H Shear; Elizabeth J Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2018 Jan - Feb

Review 7.  Toxic epidermal necrolysis and Stevens-Johnson syndrome.

Authors:  Thomas Harr; Lars E French
Journal:  Orphanet J Rare Dis       Date:  2010-12-16       Impact factor: 4.123

Review 8.  Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

Authors:  Marianne Lerch; Carlo Mainetti; Benedetta Terziroli Beretta-Piccoli; Thomas Harr
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 10.817

Review 9.  Drug-related Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Review.

Authors:  Rohini Arora; Rajesh K Pande; Shikha Panwar; Vivek Gupta
Journal:  Indian J Crit Care Med       Date:  2021-05

10.  Stevens Johnson Syndrome and Toxic Epidermal Necrolysis: Maternal and Foetal Outcomes in Twenty-Two Consecutive Pregnant HIV Infected Women.

Authors:  Lauren Knight; Gail Todd; Rudzani Muloiwa; Mushi Matjila; Rannakoe J Lehloenya
Journal:  PLoS One       Date:  2015-08-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.